Overview

Oxaliplatin in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Status:
Not yet recruiting

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborator:

Servier

Treatments:

Oxaliplatin
Trifluridine